HLB PANAGENE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,075 KRW | +0.49% |
|
-24.07% | -25.54% |
| Sales 2010 | 34.04B 24.95M | Sales 2011 | 41.45B 30.39M | Capitalization | 102B 74.94M |
|---|---|---|---|---|---|
| Net income 2010 | -4.04B -2.96M | Net income 2011 | -1.59B -1.17M | EV / Sales 2010 | 5.62 x |
| Net Debt 2010 | 10.57B 7.75M | Net Debt 2011 | 13.93B 10.21M | EV / Sales 2011 | 2.8 x |
| P/E ratio 2010 |
-43.5
x | P/E ratio 2011 |
-64.2
x | Employees | 63 |
| Yield 2010 * |
-
| Yield 2011 |
-
| Free-Float | 63.57% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.49% | ||
| 1 week | -24.07% | ||
| Current month | -26.52% | ||
| 1 month | -31.82% | ||
| 3 months | -32.27% | ||
| 6 months | -11.38% | ||
| Current year | -25.54% |
1 week
2 800.00
4 270.00
1 month
2 800.004 620.00
Current year
2 800.005 450.00
1 year
2 800.006 720.00
3 years
2 675.006 720.00
5 years
1 100.006 720.00
10 years
1 100.0012 350.00
| Managers | Title | Age | Since |
|---|---|---|---|
In-Geun Jang
CEO | Chief Executive Officer | 48 | - |
Bong-Ho Eom
BRD | Director/Board Member | 51 | 03-07-31 |
Seung-Gyo Park
BRD | Director/Board Member | 63 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chang-Shik Park
PRN | Corporate Officer/Principal | 77 | 10-02-15 |
Jong-Boo Lim
BRD | Director/Board Member | 63 | 13-03-28 |
Yong-Hwan Lee
BRD | Director/Board Member | 63 | 17-03-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 3,075 | +0.49% | 447,934 |
| 24-05-21 | 3,060 | +2.51% | 1,139,613 |
| 24-05-20 | 2,985 | +2.93% | 1,723,492 |
| 24-05-17 | 2,900 | -29.95% | 4,419,568 |
| 24-05-16 | 4,140 | +2.22% | 523,707 |
End-of-day quote Korea S.E., May 21, 2024
More quotes
HLB PanaGene Co Ltd, formerly Panagene Inc, is a Korea-based company mainly engaged in the development of genetic diagnostic products. The Company operates its business through three segments. The Diagnostics Business segment mainly involves in manufacturing and sales of molecular diagnostic reagents, analysis services, and consumables. The Materials Business segment mainly engages in the manufacturing and sales of custom pentose nucleic acid (PNA) oligomers. The Nucleic Acid Extraction segment mainly engages in the manufacturing and sales of nucleic acid extraction equipment and extraction reagents.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -25.54% | 92.07M | |
| -27.70% | 9.88B | |
| +27.06% | 2.89B | |
| -16.78% | 2.88B | |
| -15.31% | 2.12B | |
| -21.41% | 1.67B | |
| +68.70% | 1.45B | |
| +29.75% | 788M | |
| -5.02% | 741M | |
| -29.39% | 514M |
- Stock Market
- Equities
- A046210 Stock
